Comment on 'New drug candidates for depression - a nationwide population-based study'.

I would like to comment on an interesting article by Kessing et al. entitled 'New drug candidates for depression - a nationwide population-based study'(1). It presents a long-term study aimed to screen the Danish population register for the possible association between the exposure to certain clinically approved drugs: such as statins, high-dose aspirin and non aspirin nonsteroidal anti-inflammatory drugs (NSAIDs), which possess anti-inflammatory or neuroprotective properties, and the rate of incident depression. Although there has been increasing evidence that suppressing the ongoing inflammatory process could facilitate the response of patients with refractory depression to standard antidepressant drugs (2), Kessing et al. This article is protected by copyright. All rights reserved.